Wos İndeksli Açık & Kapalı Erişimli Yayınlar
Permanent URI for this communityhttps://hdl.handle.net/11727/10751
Browse
9 results
Search Results
Item Giant but Silent Lesion of the Stomach in A Geriatric Patient(2016) Etik, Digdem Ozer; Tumay, Volkan; Aktas, Hikmet; Meric, Mehmet; Zorluoglu, Abdullah; 0000-0002-6206-9332; 0000-0002-4724-0728; 27782902; A-2109-2019; AAJ-4707-2021Item Real Life Efficacy And Tolerability Of Tenofovir Alafenamde Fumarate In Liver Transplant Recipients: A Multicenter Study(2022) Gokcan, Hale; Yapali, Suna; Harputluoglu, Murat; Ellik, Zeynep Melekog. Lu; Gokcen, Pinar; Adanir, Haydar; Cosar, Arif Mansur; Durak, Serdar; Ari, Derya; Mehdiyev, Shahin; Koc, Elif Sitre; Guzelbulut, Fatih; Alkim, Huseyin; Ekmen, Nergis; Yildirim, Abdullah Emre; Unsal, Yasemin; Teker, Tufan; Etik, Digdem Ozer; Vatansever, Sezgin; Balaban, Hatice Yasemin; Ozdil, Kamil; Arslan, Mehmet; Kayhan, Meral Akdogan; Gunduz, Feyza; Kiyici, Murat; Boyacioglu, Sedat; Simsek, Halis; Tozun, Nurdan; Dincer, Dinc; Idilman, RamazanItem Preliminary Results Of The Effectiveness And Safety Of Tenofovir Alefenamide Fumarate Prophylaxis In HBV-Infected Individuals, Who Received Chemo/Immunosuppressive Therapy(2022) Gunduz, Feyza; Durak, Serdar; Unsal, Yasemin; Demir, Mehmet; Ellik, Zeynep Melekoglu; Yildirim, Abdullah Emre; Mehdiyev, Shahin; Adanir, Haydar; Demirtas, Coskun Ozer; Ucbilek, Enver; Balaban, Yasemin; Koc, Elif Sitre; Etik, Digdem Ozer; Gokcen, Pinar; Ari, Derya; Gokcan, Hale; Yapali, Suna; Ekmen, Nergis; Arslan, Mehmet; Kayhan, Meral Akdogan; Ozdil, Kamil; Sezgin, Orhan; Boyacioglu, Sedat; Simsek, Halis; Tozun, Nurdan; Dincer, Dinc; Idilman, RamazanItem Liver Transplant Experiences For The Budd-Chiarı Syndrome At Baskent University Transplant Centers(2021) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Etik, Digdem Ozer; Boyvat, Fatih; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; AAC-5566-2019; F-4230-2011; AAA-3068-2021; AAJ-8097-2021Item Efficacy And Safety Of Tenofovir Alafenamide In Hepatitis B Virus-Infected Patients With Chronic Hemodialysis And Renal Transplantation: A Preliminary Result(2021) Etik, Digdem Ozer; Boyacioglu, SedatItem Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients(2019) Etik, Digdem Ozer; Suna, Nuretdin; Ocal, Serkan; Selcuk, Haldun; Dagli, Ulku; Colak, Turan; Hilmioglu, Fatih; Boyacioglu, Ahmet Sedat; Haberal, Mehmet; 0000-0003-3719-9482; 0000-0003-0664-0976; 0000-0002-9370-1126; 30719954; ABH-4817-2020; AAE-7637-2021; S-4068-2018Objectives: The introduction of direct-acting antiviral agents has allowed significant chances for treatment for difficult-to-treat populations. This study aimed to investigate the efficacy, tolerability, and safety of these therapies in both patients with end-stage renal disease and kidney transplant recipients with chronic hepatitis C virus infection. Materials and Methods: This study was a retrospective analysis with prospective follow-up of patients. The antiviral combination of ombitasvir 25 mg, paritaprevir 75 mg, ritonavir 50 mg, and dasabuvir 50 mg was prescribed to patients with end-stage renal disease or kidney transplant recipients with noncirrhotic or compensated cirrhotic liver disease. The other antiviral combination consisted of sofosbuvir 400 mg and ledipasvir 90 mg, which was recommended to patients with decompensated cirrhosis or those who could not tolerate the first combination regimen. Ribavirin was given to all patients with genotype 1a hepatitis C virus infection. All clinical and laboratory data were recorded at week 4, at end of the treatment, and at 12 weeks after completion of treatment. Results: In terms of efficacy, sustained virologic response at 12 weeks was achieved in 94% of patients in the end-stage renal disease group and 92% of patients in the kidney transplant group. In terms of tolerability, antiviral treatment was well tolerated in both groups. Cardiac arrest and cerebrovascular accident were seen in the end-stage renal disease group; severe mucositis and glossitis were seen in the kidney transplant group. Hospitalization was needed in 2 patients for treatment of drug interactions with tacrolimus and sirolimus. Renal allograft function worsened in 2 patients, with 1 patient having biopsyproven antibody-mediated rejection. Conclusions: We observed great efficacy and safety in both kidney transplant recipients and patients with end-stage renal disease with these agents in treatment of chronic hepatitis C. However, clinicians should remain aware of drug interactions and adverse events in this fragile patient population.Item ACUTE NECROTIZING PANCREATITIS AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN A PATIENT WITH HEPATOCELLULAR CANCER: CASE REPORT AND REVIEW OF THE LITERATURE(2019) Ocal, Serkan; Suna, Nuretdin; Etik, Digdem Ozer; Bovyat, Fatih; Selcuk, Haldun; 31574073Item Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center(2019) Suna, Nuretdin; Etik, Digdem Ozer; Ocal, Serkan; Selcuk, Haldun; 31050621Objectives: Hepatocellular carcinoma is the most frequent primary malignant tumor of the liver and the third most common cause of all cancer-related mortalities. There is a need to develop new strategies to prevent hepatocellular carcinoma, as the incidence of this cancer continues to increase despite all advancements. In this study, our aim was to determine the effects of propranolol treatment on the incidence of hepatocellular carcinoma in cirrhotic patients waiting for liver transplant. Materials and Methods: We retrospectively reviewed the data of patients waiting for liver transplant with cirrhosis due to various causes registered at the Hepatocellular Carcinoma Surveillance Program between June 2011 and December 2017 in our center. These data were compared between patients using propranolol and those not using propranolol. Results: Of the 231 patients, 135 (58.4%) were male and 96 (41.6%) were female. The mean age was 58.1 +/- 14 years. We noted that 153 of total patients (66.2%) were using propranolol. Three patients (2%) were using 20 mg propranolol, 125 (81.7%) were using 40 mg propranolol, 10 (6.5%) were using 60 mg propranolol, and 15 (9.8%) were using 80 mg propranolol. Of total patients, 36 (15.6%) developed hepatocellular carcinoma, including in 12 patients (7.8%) using propranolol and 24 patients (30.8%) who did not use this agent (P < .001).Thus, the hepatocellular carcinoma frequency was 5.22 times lower in patients receiving propranolol than in those not receiving propranolol. Conclusions: Although causes of cirrhosis and initial stages were similar in both groups using and not using propranolol, incidence of hepatocellular carcinoma was significantly lower in the propranolol group than in the group without propranolol. This result showed that propranolol treatment has a protective effect for hepatocellular carcinoma in patients waiting for liver transplant with cirrhosis.